News

We are pleased to announce the first release of the Vitic Complex Nitrosamines database!

The first iteration of our database contains Ames data on 38 nitrosamines, mostly structurally complex and API-like nitrosamines.

AOP-Wiki have just announced the latest release of their web-based application for capturing, sharing and reviewing Adverse Outcome Pathway (AOP) knowledge. This latest release incorporates third party tools for the first time, one of which is Wiki Kaptis.

Lhasa Limited is pleased to announce the release of new data to its Vitic AI/PDE database users.

Lhasa Limited is pleased to announce the release of new data to Vitic Intermediates database users.

Lhasa Limited is pleased to announce the release of the 2022.1 Nitrites in Excipients database.

Effiris provides secondary pharmacology models, which have learnt from the in-house confidential data of pharmaceutical collaborators, while preserving all confidential aspects of the compounds used. As a result, Effiris overcomes one of the main challenges facing model development in drug discovery - accessing and utilising high-quality proprietary data.

The aim of the Federated Learning Hackathon - expected to launch within Q2 2022 - is to produce a federated Effiris model which outperforms the models trained in-house using only private proprietary data, at each of the participating pharmaceutical organisations. A diverse panel of nine secondary pharmacology endpoints of high interest to the pharmaceutical industry have been prioritised for the hackathon initiative...

Read the full article for more information. 

Due to the active consortium and successful member data donations into the database, Lhasa is pleased to announce that the Elemental Impurities Database is now open for all to join.

It is with great excitement that Lhasa Limited announces the launch of free tool, Wiki Kaptis. 

Wiki Kaptis is the result of an ongoing collaboration between Lhasa Limited and AOP-Wiki.

Access Wiki Kaptis for free via this article.

Lhasa Limited is excited to announce the launch of an ICH S1 consortium. The Lhasa-led consortium consists of several industry partners – all with a common goal of supporting meeting ICH S1 and reducing animal testing using Adverse Outcome Pathways (AOPs) within Kaptis.

Lhasa Limited is pleased to announce the release of Nexus 2.5, which incorporates new Derek Nexus knowledge relating to skin sensitisation, and updates to the Sarah Nexus training set to enable informed decision making on chemical safety.